NASDAQ:JANX - Nasdaq - US47103J1051 - Common Stock - Currency: USD
Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability. JANX shows excellent growth, but is valued quite expensive already.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -7.4% | ||
ROE | -7.68% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 22.52 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 58.47 | ||
Quick Ratio | 58.47 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
23.8
-0.24 (-1%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 150.87 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.39 | ||
P/tB | 1.39 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -7.4% | ||
ROE | -7.68% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 26.04% | ||
Cap/Sales | 5.71% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 58.47 | ||
Quick Ratio | 58.47 | ||
Altman-Z | 22.52 |